Extended release tablet formulations of flibanserin and method for manufacturing the same

a technology of flibanserin and extended release, which is applied in the field of extended release system, can solve the problems of difficult to find out functional excipients, difficult to develop extended release dosage forms, and formulations containing only ph-dependent retarding polymers that do not allow drug releas

Active Publication Date: 2008-02-14
BOEHRINGER INGELHEIM INT GMBH
View PDF67 Cites 60 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These physicochemical properties of basic compounds make it difficult to develop extended release dosage forms.
Formulations containing only pH-dependent retarding polymers would not allow for drug release over an extended period of time because these polymers loose their retarding effect above a certain pH.
As a result it is also difficult to find out functional excipients which would provide an improved bioavailability over the whole gastrointestinal tract for basic drugs with pH-dependent water solubility.
Therefore, calcium ions are expressly excluded, which provides a very limited usability of the proposed formulation.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Extended release tablet formulations of flibanserin and method for manufacturing the same
  • Extended release tablet formulations of flibanserin and method for manufacturing the same
  • Extended release tablet formulations of flibanserin and method for manufacturing the same

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0101] In the following a preferably process to manufacture the extended release system of the present invention is exemplarily described. However, the process steps are not intended to be of limitative character at all.

[0102] The following process steps are illustrated in the flow chart shown in FIG. 3.

[0103] The preparation of the extended release system of the present invention in the following Example usually takes place over 7 steps: [0104] step 1): preparation of the pre-mixture; [0105] step 2): preparation of the mixture for compaction; [0106] step 3): performing roller compaction; [0107] step 4): preparation of the admixture; [0108] step 5): preparation of the main mixture; [0109] step 6): preparation of the final mixture; and [0110] step 7): preparation of the tablets.

[0111] The steps will be described in the following in detail:

1. Pre-Mixture

[0112] To active substance flibanserin (200.00 g) pre-sieved (sieve size 0.5 mm) succinic acid (100.00 g), hypromellose (200.00...

example 1a

[0120]

Ingredient[mg / tablet]Flibanserin, micronised100.000Hydroxypropylcellulose100.000Microcrystalline cellulose215.000Succinic acid50.000Methacrylic acid - ethyl acrylate copolymer (1:1)25.000Silica, colloidal anhydrous2.500Magnesium stearate7.500Total500.000

example 1b

[0121]

Ingredient[mg / tablet]Flibanserin, micronised100.000Hypromellose 2208100.000Microcrystalline cellulose215.000Succinic acid50.000Methacrylic acid - ethyl acrylate copolymer (1:1)25.000Silica, colloidal anhydrous2.500Magnesium stearate7.500Total500.000

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
solubilityaaaaaaaaaa
solubilityaaaaaaaaaa
pHaaaaaaaaaa
Login to view more

Abstract

The invention is directed to a Pharmaceutical extended release system, particularly for oral administration, of a pH-dependent water-soluble active substance, comprising or essentially consisting of a) flibanserin or a pharmaceutically acceptable derivative thereof as active substance; b) one or more pharmaceutically acceptable pH-dependent polymers; c) one or more pharmaceutically acceptable pH-independent polymers; d) one or more pharmaceutically acceptable acids; and e) optionally one or more additives. The present invention provides a release profile of flibanserin which is independent on the pH in the gastrointestinal tract when administered orally resulting in a significantly improved bioavailability.

Description

[0001] This application claims the benefit of priority to EP 06 118 896, filed Aug. 14, 2006, the contents of which are incorporated herein by reference in its entirety. FIELD OF THE INVENTION [0002] The present invention is directed to an extended release system, particularly for oral administration, of flibanserin and a method for the production thereof. BACKGROUND OF THE INVENTION [0003] The invention relates to novel extended release systems for basic drugs with pH-dependent water solubility such as flibanserin. Flibanserin is a known benzimidazolon derivative having the summation formula C20H21F3N4O represented by the chemical indication 1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-2H-benzimidazole-2-one which was already disclosed in 1992 in form of its hydrochloride in EP-A-526 434 and has the following chemical formula: [0004] Flibanserin is a known post-synaptic full serotonin (5-HT1A) agonist and 5-HT2A antagonist. It is therefore a promising thera...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/22A61K31/496A61P25/00A61P3/04A61P9/00
CPCA61K9/2013A61K9/2018A61K31/496A61K9/2054A61K9/209A61K9/2027A61P25/00A61P25/24A61P3/04A61P9/00
Inventor EISENREICH, WOLFRAMFRIEDL, THOMAS
Owner BOEHRINGER INGELHEIM INT GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap